Quote:

---

A two drug combo for viral reduction makes little sense for CYDY.

---

Exactly ohm. I was pointing out that leronlimab will be bigger than combo MDR2+ market, with a very high probability. 1) monotherapy or 2) backup plan to 1 as a combo 2 drug once a week, which would only be implemented if 1 failed

On the mono pivotal trial being approved, did you catch Dr. Lalezari's discussion.


15:40 I'm glad to see that the FDA is working
15:44 with high design to try and figure out
15:45 how both to help them cross the finish
15:49 line for their approval in the salvage
15:52 of the treatment experience population
15:55 and obviously they've given a fast track
15:58 designation and they are engaging
16:01 cytodyn in conversation as to what a
16:02 phase 3 mono therapy study would
16:04 look like in the meantime

Why would he know?

38:12 September once we hear back from FDA
38:15 that should be finalized we have
38:17 monotherapy that FDA as you heard dr.
38:19 Jay Lalezari said that we are they're
38:21 working with us dr. Jay Lalezari by the
38:24 way had gone to everyone almost every
38:26 one of those FDA meeting in person so
38:29 he's very much aware of the FDA's
38:31 position with us so monotherapy